Nancy D. Santos
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.
Journal: IUCrJ
Published: February 09, 2026
A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention.
Journal: International journal of pharmaceutics
Published: January 30, 2026
Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer.
Journal: Cancers
Published: November 03, 2022
Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: March 31, 2022
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Journal: Molecular cancer therapeutics
Published: April 04, 2018
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Journal: The Journal of pathology
Published: December 21, 2016
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Journal: Nature communications
Published: June 01, 2016
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Journal: Investigational new drugs
Published: May 12, 2014
Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
Journal: Nanomedicine (London, England)
Published: April 22, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026